Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 961 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05644717RecruitingPhase 4
Testing erugliflozin for fatty liver and diabetes control
This trial studies whether erugliflozin can reduce liver fat and liver scarring (fibrosis) while also improving blood sugar in people with type 2 diabetes and fatty liver disease (NASH/NAFLD). It’s designed for people who haven’t used certain diabetes medicines like SGLT2 inhibitors or insulin before.
Peshawar, KPKAges 18–65 - NCT05648214RecruitingPhase 1/Phase 2
Testing a new liver medicine in people with fatty liver
This early-phase study tests whether ALN-PNP is safe and well tolerated, first in healthy adults and then in adults with MASLD (fatty liver disease). If you have MASLD, it may help researchers learn whether this medicine is a promising option for treating liver fat buildup.
Glendale, CaliforniaAges 18–75 - NCT05648591RecruitingPhase 4
Iloperidone study for teens with schizophrenia or bipolar I
This Phase 4 study checks how safe and well-tolerated iloperidone is when used in a typical, open-label way for teenagers. It may help doctors better understand side effects and safety in teens with schizophrenia or bipolar I disorder.
Little Rock, ArkansasAges 12–17 - NCT05660642RecruitingPhase 2
Safety and tolerability study for BPL-003 in hard-to-treat depression
This Phase 2 study tests BPL-003 in people with treatment-resistant depression to learn about its safety and how it affects the body and brain. Because it is open-label, everyone knows they are getting the study treatment, and you’ll also need to stop your current antidepressant during the study.
LiverpoolAges 18–75 - NCT05672121RecruitingPhase 1/Phase 2
Gene therapy safety study for neovascular macular degeneration
This trial tests a new gene therapy drug (KH631) to see if it is safe and tolerated in people with neovascular age-related macular degeneration (nAMD). It may help your retina problems, but the early goal is mainly to learn about side effects and how the treatment behaves in the eye.
BeijingAges 50–85 - NCT05674656RecruitingPhase 1/Phase 2
Testing dolutegravir and rilpivirine in HIV-positive children
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
Long Beach, CaliforniaAges 6–12 - NCT05682378RecruitingPhase 3
Long-term follow-up for inclisiran in young people with inherited high cholesterol
This study follows people with HeFH or HoFH (inherited high cholesterol) who previously took inclisiran in specific pediatric ORION studies. It mainly checks long-term safety and how well the treatment continues to be tolerated over time.
Boca Raton, FloridaAges 12–100 - NCT05683418RecruitingPhase 1
Study of a new drug for PIK3CA-mutated HR+ HER2- breast cancer
This early-stage study tests the safety and tolerability of TOS-358 in women with HR-positive, HER2-negative breast cancer that has a specific gene change (PIK3CA). It may help learn whether this targeted treatment is safe enough to move forward.
Chicago, IllinoisAges 18 years+ - NCT05690581RecruitingPhase 1
CM369 for advanced cancers with special immune marker in tumors
This Phase 1 study tests how safe and tolerable CM369 is in people with advanced solid tumors or blood cancers. It also looks at how the drug behaves in the body and whether it can help shrink or control cancer, especially when a tumor marker called CCR8 is present.
Guangzhou, GuangdongAges 18–75 - NCT05707325RecruitingEarly Phase 1
Testing a lab-made red blood cell treatment for advanced cancers
This early trial studies whether an engineered (lab-made) red blood cell treatment is safe and tolerable, and whether it may show early anti-cancer activity. It may help people with advanced cancers whose disease has not responded well to standard options.
Hangzhou, ZhejiangAges 18–75 - NCT05719779Recruiting
Oral device trial for snoring and sleep apnea in throat cancer
This trial tests whether a custom mouth (mandibular advanced) device can reduce snoring and breathing pauses during sleep in people with oropharyngeal (throat) cancer. It also looks at how well you tolerate the device and whether it helps with sleep symptoms.
Montreal, QuebecAges 18–65 - NCT05720780Recruiting
Music-based rehab training for people with COPD and low oxygen
This trial studies whether combining music with exercise training can improve breathing ability and exercise tolerance in people with COPD and chronic low oxygen. It also looks at whether the program is safe for people who are stable on long-term oxygen.
Telese Terme, BeneventoAges 40–85 - NCT05732831RecruitingPhase 1/Phase 2
Study drug for tumors with MTAP loss
This Phase 1/2 trial tests TNG462 (with or without pembrolizumab, depending on the plan) in solid tumors that have lost MTAP. The goal is to check safety and learn whether the treatment can help people with these specific tumor changes.
Palo Alto, CaliforniaAges 18 years+ - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Orlando, FloridaAges 18 years+ - NCT05735184RecruitingPhase 1
Ziftomenib with AML medicines for NPM1- or KMT2A-mutated leukemia
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
Phoenix, ArizonaAges 18 years+ - NCT05757687Recruiting
Omega System for urinary symptoms from enlarged prostate
This trial studies a device called the Omega System to see if it is safe and effective for urinary problems caused by an enlarged prostate (BPH). You may be a better fit if you have moderate-to-severe symptoms and prostate measurements that match the study plan, and if you are scheduled for prostate surgery or need evaluation for BPH.
TbilisiAges 50 years+ - NCT05778188RecruitingPhase 2
RLS-0071 for newborns with moderate or severe HIE
This trial studies whether RLS-0071 is safe and can help some newborns with moderate or severe hypoxic-ischemic encephalopathy (HIE), a brain injury caused by low oxygen around birth. Babies in the study also receive standard whole-body cooling (therapeutic hypothermia), and the researchers will watch for side effects and early signs of benefit.
Little Rock, ArkansasAges Up to 10 hours - NCT05791864RecruitingPhase 1/Phase 2
Gene therapy for vision loss in CLN2, tested for safety
This early-phase trial studies a gene therapy medicine called TTX-381 to see if it is safe and tolerable in people with CLN2 disease that affects the eyes. The study also looks at how well the treatment fits into existing eye enzyme therapy care.
HamburgAges 1–7 - NCT05795140RecruitingPhase 3
Long-term safety study of iptacopan for aHUS
This study follows people with aHUS who are already taking iptacopan to check how well it continues to work and how safe it is over the long term. You may be asked to keep taking the study medicine and follow extra safety rules, including infection and pregnancy precautions.
São Paulo, São PauloAges 18–100 - NCT05806099RecruitingPhase 1/Phase 2
Study of MBS303 for CD20-positive B-cell lymphoma that returned
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
BeijingAges 18 years+ - NCT05819892RecruitingPhase 1
Dostarlimab with chemo and radiation for advanced womb cancer
This Phase 1 trial studies how safe and tolerable it is to add dostarlimab (an immunotherapy) to standard chemo and radiation, followed by more chemotherapy, for stage IIIC endometrial cancer that has spread to lymph nodes. It aims to see whether this combination can be given safely soon after surgery.
Houston, TexasAges 18 years+ - NCT05828511RecruitingPhase 1/Phase 2
Study drug for newly diagnosed myeloma before standard treatment
This trial tests linvoseltamab (a new targeted immune treatment) to see if it’s safe and how well it works in adults with recently diagnosed multiple myeloma who haven’t started treatment yet. Because it’s a “window of opportunity” study, it’s meant to learn early results before standard therapy is fully underway.
Los Angeles, CaliforniaAges 18 years+ - NCT05836259RecruitingPhase 1/Phase 2
TN-201 for heart symptoms from MYBPC3 heart disease
This early trial tests TN-201 to see how safe it is and how well it works to reduce symptoms in adults with MYBPC3-related hypertrophic cardiomyopathy. It’s designed to learn safe dosing, and you may be eligible if you have specific genetic heart changes and ongoing symptoms.
La Jolla, CaliforniaAges 18–75 - NCT05836896RecruitingPhase 1
Safety check of BCMA CAR T-cells made from your own immune cells
This early-phase trial tests whether a personalized BCMA-targeting CAR T-cell treatment is safe and what dose is tolerable in people whose lymphoma or myeloma has come back or did not respond to prior treatment. If you qualify, the team will monitor you closely for side effects to find the safest maximum tolerated dose.
DresdenAges 18 years+
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 961 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.